(Reuters) -The U.S. Food and Drug Administration has approved Regeneron (NASDAQ: REGN )’s cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

The FDA’s nod for the therapy, branded Lynozyfic, comes after a setback last year when the regulator declined to approve it after an inspection at a third-party manufacturer.

Lynozyfic was greenlit by the regulator to treat patients with multiple myeloma who have received at least four prior lines of therapy.

Multiple myeloma is a commonly recurring cancer. Over 36,000 new cases are estimated to be diagnosed in the U.S. in 2025, according to the American Cancer Society.